logo
Music festivals have become more open to harm reduction initiatives. How far will it go?

Music festivals have become more open to harm reduction initiatives. How far will it go?

NEW YORK (AP) — The sounds of muffled percussion and audience cheers reverberate throughout the grounds. Brand activations, makeshift bars and restaurant pop-ups control traffic as a sea of bodies move from set to set. Sandwiched between is a row of nonprofits across familiar causes: hunger, housing and voter registration.
It's a common music festival scene, until closer inspection. There is a new table, This Must Be the Place. The Ohio-based nonprofit offers attendees free opioid overdose reversal treatment and training on how to use it, an education acquired in under two minutes. Just a few years ago, their inclusion might've been unthinkable amid murky regulations and a lack of public awareness surrounding harm reduction.
Advocates say drugs are commonly consumed at music festivals, making them ideal locations for harm reduction activities. While more music festivals are allowing such activities, activists are pushing for expanded efforts as some festivals remain cautious.
Harm reduction varies at festivals across the country
Founded by William Perry and Ingela Travers-Hayward in 2022, This Must Be The Place has since given away an estimated $4.5 million in naloxone, the opioid overdose reversal medication, at festivals and smaller community events.
In the very beginning, without a 'proof of concept,' as Perry describes it, they had trouble partnering with festivals. Eventually, a few festivals in the Midwest agreed to let them table, which 'got us in the door with Bonnaroo in 2022,' says Perry, referring to the major U.S. festival operated by C3 Presents, one of the largest concert promoters on the planet. Now they have a presence at 35 major U.S. festivals — including Lollapalooza, Governors Ball and Besame Mucho — where they collaborate directly with C3 and their security personnel.
The organization's growth overlaps with advancing federal regulations. According to Daliah Heller, vice president of overdose prevention initiatives at the global public health nonprofit Vital Strategies, naloxone distribution used to be determined by state regulations until 2023, when the Food and Drug Administration approved the first over-the-counter nasal spray.
'We no longer need the prescription laws to be amended to allow for the distribution of naloxone,' she says. 'Now it's like buying aspirin — it's over the counter.'
Last year, This Must Be the Place gave away 46,146 units of Narcan — a brand name for naloxone — through their national festival outreach.
Emmett Beliveau, chief operating officer of C3 Presents, says working with This Must Be the Place was C3's first time implementing public-facing harm reduction strategies, in addition to the promoter's existing medical programs.
Bringing the organization into C3's festivals was 'not in response to anything that has happened at one of our festivals,' he says, but rather because of the 'number of fatalities happening in our communities.'
Some attendees have taken matters into their own hands
Some activists believe attendees are most responsive to receiving harm reduction education from peers instead of authority figures. And so, for the last three years, a nonprofit dedicated to combating accidental drug overdoses among young adults, Team Awareness Combating Overdose, has distributed fentanyl test strips and Narcan at the Coachella Valley Music and Arts Festival.
Former TACO CEO Kameran Mody says that music festivals are ideal locations for distribution and education because 'music and the use of drugs are synonymous with each other.'
TACO distributes through what Mody describes as 'guerrilla-style marketing.' They enlist volunteers, train them on how to use naloxone, and ship Narcan and test strips to them to bring into the festival.
They do not involve the festival organizers. Representatives for Coachella did not respond to The Associated Press' requests for comment.
In 2023, a TACO volunteer administered Narcan to an unresponsive Coachella attendee exhibiting signs of an overdose. The organization says the attendee regained consciousness.
'That was one of our biggest successes,' Mody says.
Local laws and the risk of criminalization hinder initiatives
In 2019, at Bonnaroo, a 27-year-old man was found dead at his campsite — right after harm reduction activists had picketed the Tennessee festival because it didn't allow drug testing. The toxicology report found ecstasy and fentanyl in his system.
At the time, under state law, test strips were criminalized and classified as drug paraphernalia. That's changed: In 2022, Tennessee decriminalized fentanyl test strips. By the end of 2023, 44 other states and D.C. had done the same.
But in some states, drug paraphernalia laws are written in a way that isn't completely transparent — there are test strips that are not fentanyl-specific, Heller points out — and criminalization and social stigmas endure.
Some have found workarounds. 'Even in the states where the legalities were a bit unclear, instead of just coming in and hoping things worked out, we would reach out to the health department, and say 'We run this project, how do feel about it?'' says Perry. 'We would end up with letters from the highest-ranking health official, either in the county or in the state, saying 'We approve of this.' That circumvented any roadblocks.'
Some festivals, though, might be hesitant to use test strips because 'it's tough for them to admit that drugs are being used,' Mody says. Some festivals have even banned naloxone.
While This Must Be The Place distributes fentanyl test strips at some Ohio events, C3 doesn't distribute test strips at its events and does not plan to. Beliveau doesn't believe fentanyl test strips are effective and expressed concern they could encourage drug use. Test strips, which can detect fentanyl in pills, powders or injectables, are recommended by the Centers for Disease Control and Prevention as a low-cost means of helping prevent drug overdoses.
Harm reduction shows promise outside the US
At a three-day electronic music festival in Mexico City earlier this year, a booth provided free, anonymous drug testing. The initiative, known as 'Checa tu Sustancia' (Check Your Substance), was spearheaded by the Instituto RIA, a Mexico-based drug policy research and advocacy organization.
When unexpected substances are detected, users received detailed information on what they are, their risks, potential interactions with other substances and dosage adjustments, empowering them to make informed choices.
Perry says they are aware of smaller festivals in the United States conducting drug checking, but 'they do it in a very underground and whisper network way' to avoid criminalization.
What Perry says his organization would like to see at music festivals in the future would be harm reduction areas — sections where attendees who have taken drugs can be monitored, not to 'get them into trouble' but to ensure safety.
Heller says there are a number of groups working to destigmatize drugs, promote decriminalization, and promote drug checking.
'We already have drug checking happening in cities,' she says. 'It makes perfect sense to expand the settings where you would offer that to include music festivals. It's the same rationale. ... The issue is this idea of liability. You'd have to create a law, essentially, that would protect the festival from liability.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gaza Hospital Director Killed in Israeli Airstrike
Gaza Hospital Director Killed in Israeli Airstrike

Time​ Magazine

timean hour ago

  • Time​ Magazine

Gaza Hospital Director Killed in Israeli Airstrike

Dr. Marwan Sultan, the director of the Indonesian Hospital in Gaza City, was killed in an Israeli airstrike on Wednesday, according to relatives and the Gaza Health Ministry. The doctor was killed alongside his wife, sister, daughter and son-in-law when a missile hit the apartment where the family where staying, his surviving daughter Lobna said. 'A missile was dropped on his room exactly, on his place, on him precisely. All the rooms were fine except for his; the missile hit it precisely,' she added. The Israel Defense Forces (IDF) said in a statement to TIME that it struck a 'key Hamas terrorist' on Wednesday during an operation in Gaza City. 'The claim that as a result of the strike uninvolved civilians were harmed is being reviewed. The IDF regrets any harm to uninvolved individuals and operates to mitigate harm to them as much as possible,' it said. Medical Aid for Palestinians (MAP) condemned the death, describing Sultan as 'a dedicated medical professional who had worked under unimaginable conditions to provide care to patients trying to survive months of Israel's military bombardment and blockade.' Death of doctor adds to rising toll of healthcare workers in Gaza war MAP says that the number of healthcare workers killed in Gaza has now reached at least 1,580 since the start of the Israel-Hamas war in October 2023. 'Despite being protected under international law, Gaza's healthcare workers are being erased before the world's eyes,' MAP said in a statement in response to Sultan's death on Wednesday. Healthcare Workers Watch (HWW), a Gaza-based organization, said that Sultan's death brings the number of healthcare workers killed by Israeli airstrikes to 50 over the past 70 days. The Indonesian Hospital, which Sultan managed, was forced to close in May after 'repeated Israeli attacks and sustained structural damage,' according to the United Nations. Sultan had at the time described the Israeli attacks as a 'direct targeting of the hospital, including the intensive care unit.' Gaza's health system strained under sustained Israeli attacks The World Health Organization (WHO) last month said that there were no more functioning hospitals left in northern Gaza, with the health system across the whole of the strip 'collapsing.' The deterioration of the enclave's health system comes with repeated strikes targeting hospitals. WHO said patients sheltering in the courtyard of Al-Aqsa Hospital, Deir al-Balah, were injured in an Israeli airstrike on Tuesday, adding that it has documented 734 attacks on health facilities in Gaza since the start of the war. The International Committee for the Red Cross said that it is 'alarmed by the intensifying hostilities' in Gaza and that its Field Hospital is overwhelmed as a result. The ICRC urgently reiterates its call for the protection of medical personnel and medical facilities in Gaza. They must be respected and protected to safeguard a lifeline for the wounded and sick,' a statement read. The Gaza Health Ministry reported that 118 Palestinians have been killed in the last 24 hours, bringing the total deaths in Gaza to over 57,000 since the start of the war. The ministry is the primary source for casualty data relied upon by humanitarian groups, journalists, and international bodies in the absence of independent monitoring on the ground. The war was triggered after the Hamas terror attack on Israel on Oct. 7, 2023, killing over 1,200 people and taking around 250 hostages.

Surmodics still recovering after June cyberattack
Surmodics still recovering after June cyberattack

Yahoo

timean hour ago

  • Yahoo

Surmodics still recovering after June cyberattack

Surmodics has revealed that it is still recovering after it was hit by a cyberattack in June 2025. In a Form 8-K filed with the US Securities and Exchange Commission (SEC), the maker of the Pounce XL thrombectomy system for clot removal said that on 5 June, the US-based company discovered that a third party had gained unauthorised access to 'certain' IT systems, rendering them 'unavailable' to the company. Surmodics has been able to continue accepting customer orders and shipping products without any customer impact by using alternative IT systems following the breach. The company noted that to its knowledge, the threat actor had not released any of its data, including any third-party data, or used any such data for any fraudulent purposes. It continues to evaluate the 'scope and details of the IT data' stolen in the attack. Containment measures were initiated once the breach was identified, with certain IT systems taken offline. Surmodics added that it implemented its security incident response plan and that remaining IT systems and data are currently being restored and validated. Surmodics is not the only medtech company to have experienced a cyberattack this year. In May, medical technology company Masimo revealed that 'unauthorised activity' had been detected on its on-premise network in April. The incident disrupted certain activities at the patient monitoring company's manufacturing facilities and hindered its ability to process and ship customer orders effectively. According to Masimo, the attack did not affect its cloud-based hospital data systems, with no evidence of any employee or patient data being compromised. Research indicates that cyberattacks on healthcare organisations are on the rise, due in part to outdated legacy systems and increased vulnerabilities due to the rise of Internet of Things (IoT) devices and the overall richness of the data available to bad actors. According to KPMG, due to cyber threats, the functioning of healthcare systems has reached a 'tipping point'. With the rise of AI-powered medical transcription tools being deployed in healthcare systems, KPMG states that there is an increasing onus on chief information security officers (CISOs) to ensure that data privacy, access management, and other security protocols are well-developed as a means to protect sensitive patient information. According to GlobalData, cybersecurity spending by healthcare providers is growing at a CAGR of 12.5% to reach a valuation of $10.9bn by 2027. "Surmodics still recovering after June cyberattack" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

Yahoo

time5 hours ago

  • Yahoo

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royalties CLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, has exercised its option to license Abeona's patented AAV204 capsid for use in potential gene therapies for a range of prevalent and rare retinal diseases that result in blindness. This worldwide, non-exclusive license is pursuant to the agreement between Abeona and Beacon, announced in July 2024, to evaluate the therapeutic potential of AAV204. AAV204, a novel AAV capsid from the AIM™ capsid library licensed by Abeona from the University of North Carolina at Chapel Hill, has been shown to achieve high macular and optic nerve transduction levels after para-retinal administration and has also been shown to facilitate transduction of both the inner and outer retina after intravitreal administration in mice and non-human primates. 'Beacon's option exercise further validates AAV204's potential to enable targeted delivery of gene therapies in rare and prevalent ophthalmic diseases,' said Dr. Madhav Vasanthavada, Chief Commercial Officer and Head of Business Development at Abeona Therapeutics. 'Our non-exclusive agreement with Beacon enables us to fully explore the therapeutic value of AAV204 in additional ophthalmic diseases.' The exercise of this license option concludes Beacon's initial evaluation of the AAV204 capsid for development and commercialization of gene therapies and gives Beacon the right to use AAV204 in connection with up to five gene or ophthalmology disease targets. Under the terms of the agreement, Abeona will receive an undisclosed upfront license payment with additional payments upon the achievement of certain development, regulatory, and sales milestones, along with tiered royalties on worldwide net sales for licensed products incorporating AAV204. About the AIM™ capsid libraryThe AIM™ capsid library is a collection of novel AAV serotypes that target delivery of genetic payloads to key tissues implicated in devastating genetic diseases, including the central nervous system (including the retina), lungs, eye, muscle, liver and other tissues, with potentially improved tropism profiles. AIM™ vectors have shown the potential to evade the immune response generated by exposure to naturally-occurring AAV vectors in preclinical studies. AAV204 is covered by U.S. Patent Nos. 10,532,110 and 10,561,743. About Abeona TherapeuticsAbeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona's ZEVASKYN™ (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company's fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company's development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona's novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit ZEVASKYN™, Abeona Assist™, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc. Forward-Looking Statements This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as 'may,' 'will,' 'believe,' 'anticipate,' 'expect,' 'intend,' 'potential,' and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to commercialize ZEVASKYN, the therapeutic potential of ZEVASKYN, whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company's expectations, continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections from the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company's most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws. CONTACT: Investor and Media Contact: Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@ in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store